Basket | Login | Register

 
 
 
 

2015 Accounts

Financial accounts

Balance sheet as of December 31, 2015


 

2015 (Euro)

2014 (Euro)

ASSETS

   

Fixed assets

   

Other fixed assets

29,066

28,597

Current assets

   

Debtors European Commission

167,803

123,382

Other debtors

231,650

31,653

Cash at bank and on deposit

556,999

167,130

 

956,452

322,165

Prepayments

5,554

2,589

 

991,072

353,350

LIABILITIES

   

Capital and reserves

   

Results brought forward

197,798

183,738

Result of the year

19,763

14,060

 

217,562

197,798

Creditors

   

Amounts owed to credit institutions

EU Subsidies received on account

395,583

55,596

Tax and social security

27,163

19,456

Payments received on account

250,000

 

Trade creditors

48,367

51,149

Other liabilities

31,324

20,291

 

752,437

146,492

Deferred income

21,074

9,060   

 

991,072

353,350

Deferred income represents a part of income received in 2015 and which will be used in 2016.

As at December 31, 2015, the non-profit organisation had a rental guarantee of KEUR 16 granted to the owner of the offices used by the non-profit organisation.

Profit and loss account – Year ended December 31, 2015


 

2015 (Euro)

2014 (Euro)

Support and revenue

   

Other operating income

   

EU Subsidy

611,498

465,297

Corporate sponsorship

287,386

296,608

Sponsorship received on account

-21,074

-9,060

AE Conference registration fees

123,191

164,362

Project participation and other subsidies

98,153

109,915

Co-financing in kind

85,200

56,700

Membership fees and contributions

58,377

57,790

Deferred income

9,060

5,991

Publication sales and royalties

1,712

5,693

Donations

574

498

Other operating income

6,846

9,248

External charges

   

Accommodation expenses

-200,638

-172,543

External experts

-140,403

-142,542

Publication and Information material

-79,869

-95,053

Travel expenses

-74,075

-59,274

Office rent and associated costs

-41,220

-47,646

Alzheimer Europe Foundation

-40,686

-29,422

Communication costs

-39,957

-31,572

Equipment and Leasing

-15,185

-33,561

Office stationery and related costs

-3,454

-7,486

Bank charges

-3,023

-4,203

Membership fees

-1,120

-1,000

Other costs

-1,517

-67

Staff costs

   

Wages and salaries

-521,716

-448,171

Social security costs

-68,486

-67,532

Depreciation

-10,670

-9,469

Interest receivable and similar income

860

558

 

19,763

14,060


In 2015, Alzheimer Europe had an audited income of EUR 1,261,781.96 of which EUR 857,376.42 (67.95%) were for the organisation’s core activities (including the organisation’s Annual Conference) and EUR 404,405.54 (32.05%) were for the organisation’s annual conference, corporate affairs activities and other projects.

Funding of core activities (EUR 857,376.42)

In 2015, the core funding of Alzheimer Europe was composed as follows:

  • EUR 422,880 (49.32%) from public funding,
  • EUR 96,294.80 (11.23%) from foundations and other non-profit organisations,
  • EUR 137,877.29 (16.08%) from member organisations,
  • EUR 75,700 (8.83%) from corporate sources,
  • EUR 123,764.76 (14.44%) from private individuals,
  • EUR 859.57 (0.10%) from bank interest and similar.

Public funding

In 2015, Alzheimer Europe received EUR 422,880 as an operating grant from the European Commission

Foundations and organisations

The EUR 96,294.80 which Alzheimer Europe received in 2015 from foundations and other non-profit organisations can be broken down as follows:

  • EUR 87,000 as direct support from Fondation Alzheimer, Luxembourg,
  • EUR 5,294.80 from Fondation Roger de Spoelberch for the publication of the Alzheimer Europe Care Manual in Portuguese,
  • EUR 4,000 from Fondation Médéric Alzheimer to support AE’s work on ethical challenges faced by professional carers.

Funding from member organisations

In 2015, the EUR 137,877.29 funding from member organisations can be broken down as follows:

  • EUR 58,377.29 in membership fees and contributions
  • EUR 79,500 in co-financing from Board members and representatives of member organisations in time donated to the organisation (at EUR 300 per day).

Corporate support

In 2015, Alzheimer Europe received EUR 75,700 from corporate sources as core-funding which can be broken down as follows:

  • EUR 35,000 from GlaxoSmithKline as support to the organisation’s core activities,
  • EUR 10,000 from Hoffmann-LaRoche and Lilly to support the AE Conference in Ljubljana,
  • EUR 5,700 from Newsweaver which provided an e-mail facility free of charge,
  • EUR 5,000 from Nestlé, Piramal and SCA Global Hygiene to support the AE Conference in Ljubljana.

Private individuals

In 2015, AE received EUR 123,764.76 from individuals which can be broken down as follows:

  • EUR 123,191.25 in conference registrations and
  • EUR 573.51 in donations.

Bank interest and similar

In 2015, Alzheimer Europe had an income of EUR 859.57 from bank interest and similar income.

Funding of project activities (EUR 404,405.54)

In 2015, Alzheimer Europe received EUR 404,405.54 for its participation in various EU projects, a project on good incontinence care and its corporate affairs activities, of which

  • EUR 217,385.51 (53.75%) came from corporate sponsors
  • EUR 1,712.04 (0.42%) from private individuals,
  • EUR 188,617.52 (46.64%) from public sources and
  • EUR 8,704.32 (2.15%) from foundations and other non-profit organisations,
  • EUR -12,013.85 (-2.97%) was project income deferred to 2016.

Corporate support

The corporate support received by Alzheimer Europe for its activities in 2015 (EUR 217,385.51) can be broken down as follows:

  • Lilly contributed EUR 41,280 as a gold sponsor of AE’s corporate programme and as travel support,
  • SCA Global Hygiene contributed EUR 32,350 as a bronze sponsor of AE’s corporate programme and towards the AE/SCA joint project on good incontinence care,
  • Hoffmann-LaRoche contributed EUR 20,025 as a silver sponsor of AE’s corporate programme and as travel support,
  • GE Healthcare and Janssen contributed EUR 20,000 each as silver sponsors of AE’s corporate programme,
  • Nutricia contributed EUR 15,000 towards AE’s corporate programme,
  • Lundbeck, Nestlé and Otsuka contributed EUR 12,500 each towards AE’s corporate programme,
  • Merz and Piramal provided EUR 10,000 as bronze sponsors of AE’s corporate programme,
  • Sandoz and Biogen provided EUR 5,000 as sponsors of AE’s corporate programme
  • GSK provided EUR 1,230.51 in travel support and honoraria.

Private individuals

In 2015, Alzheimer Europe received EUR 1,712.04 in publication sales.

Public funding

In 2015, Alzheimer Europe received EUR 188,617.52 as public funding from its participation in various EU projects:

  • EUR 52,650,11 for EPAD,
  • EUR 26,411.36 for AETIONOMY,
  • EUR 23,212.33 for AFE-INNOVNET,
  • EUR 22,757.35 for PharmaCog,
  • EUR 15,786.22 for PredictND,
  • EUR 14,119.52 for PACE,
  • EUR 9,628.72 for NILVAD,
  • EUR 9,561.46 for Smart4MD,
  • EUR 7,370.98 for a JPND health outcomes project and
  • EUR 7,119.47 for EMIF.

Foundations and organisations

In 2015, Alzheimer Europe received a total of EUR 8,704.32 for other organisations and foundations, including EUR 6,846.27 from various organisations as travel grants and EUR 1,858.05 for secretarial costs provided to the Alzheimer Europe Foundation.

Deferred income

In 2015, Alzheimer Europe was able to contribute EUR 9,060.19 to its project activities which came from deferred income in 2014 and reported EUR 21,074.04 of its project income to 2016.

Overall funding

The following table lists all sources of income received in 2015.

In line with the policy of the European Medicines Agency on transparency requirements for accredited patients’ organisations, this is presented in total amounts as well as in terms of percentages of the overall income of the organisation.

Funding source

Funding received (2015)

As % of AE income (2015)

As % of AE income (2014)

Lilly

51,280.00

4.06%

4.46%

GlaxoSmithKline

36,230.51

2.87%

3.01%

Hoffmann-LaRoche

30,025.00

2.38%

1.74%

GE Healthcare

20,000.00

1.59%

0.86%

Janssen

20,000.00

1.59%

1.72%

Piramal

15,000.00

1.19%

1.29%

Lundbeck

12,500.00

0.99%

0.90%

Otsuka

12,500.00

0.99%

 

Merz

10,000.00

0.79%

0.86%

Biogen

5,000.00

0.40%

 

Sandoz

5,000.00

0.40%

0.43%

Novartis

 

 

0.86%

Pfizer

   

0.86%

Sub-total: Pharmaceutical funding

217,535.51

17.24%

16.98%

SCA Global Hygiene

37,350.00

2.96%

3.57%

Nestlé

17,500.00

1.39%

0.64%

Nutricia

15,000.00

1.19%

1.72%

Newsweaver

5,700.00

0.45%

0.49%

Bupa

 

 

0.86%

Kaizo

 

 

1.72%

Sub-total: Other corporate sources

75,550.00

5.99%

9.00%

Total: Corporate funding

293,085.51

23.23%

25.98%

European Commission

611,497.52

48.46%

39.99%

Scottish Government

 

 

1.17%

Total: Public funding

611,497.52

48.46%

41.15%

Fondation Alzheimer, Luxembourg

87,000.00

6.90%

7.48%

Other organisations

6,846.27

0.54%

2.71%

Fondation Roger de Spoelberch

5,294.80

0.42%

 

Fondation Médéric Alzheimer

4,000.00

0.32%

 

Alzheimer Europe Foundation

1,858.05

0.15%

 

Life Changes Trust

 

 

0.80%

Malta Tourism Authority

 

 

 

Total: Foundations and organisations

104,999.12

8.32%

10.99%

Individuals (Conference fees, donations, publications)

125,746.08

9.94%

14.21%

Total: Individuals

125,746.08

9.94%

14.21%

AE member organisations

137,877.29

10.93%

6.64%

Total: Member organisations

137,877.29

10.93%

6.64%

Deferred income

-12,013.85

-0.95%

-0.26%

Total: Deferred income

-12,013.85

-0.95%

-0.26%

Bank interest and similar

859.57

0.07%

0.05%

Total: Bank interest and similar

859.57

0.07%

0.05%

Other income

 

 

1.24%

Total: Other income

 

 

1.24%

Total Income

1,261.781.96

100.00%

100.00%

 

 
 

Last Updated: Friday 11 November 2016

 

 
 

Options